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Norbert Wodarz, Jfirgen Fritze , Johannes Kornhuber, and 
Peter Riederer 
3H-spiroperidol binding to lymphocytes has been proposed as a vulnerability marker for 
schizophrenia. However, the biological significance and even existence of this "binding 
site" are still in controversy. Therefore, the present study reevaluated methodological 
details using a filtration binding assay. The results indicated that some well-known, but 
obviously uncontrolled pitfalls might contribute to this controversy [e.g., unspecific filter 
binding, which increased in the presence of (+)-butaclamol, or a variable amount of 
contaminating granulocytes). Moreover, due to an atypically shaped saturation curve, 
different mathematical methods to analyze the data were used and compared. The present 
data should help us to understand the biological relevance of this marker, as viewed in 
different laboratories. 
Introduction 
In recent years research in the field of psychiatry focused on the evaluation of biological 
markers. For reasons of clarity it is of bene,~t to distinguish state-dependent (state) from 
state-independent (trait) markers. A state-independent feature could improve diagnostic 
validity and identify subgroups. Moreover, itmight make it possible to identify individuals 
at risk. Recently, increased binding of 3H-spiroperidol to peripheral lymphocytes was 
reported to be a trait marker in schizophrenic patients (Boedy and Ackenheil 1987). 
The pathophysiology of schizophrenia s still not known. To date the dopamine hy- 
pothesis of schizophrenia is favored, since antipsychotic drugs are thought o act by 
blocking D2 dopamine receptors (Seeman et al 1976). Previous evidence from postmortem 
studies that showed significantly increased striated D2 doparnine r ceptors inschizophrenic 
patients (Cross et al 1981; Mita et al 1986) has recently ,been ascribed to neuroleptic 
treatment prior to death (Kornhuber et al 1989). In vivo s~xdies using positron emission 
tomography (PET) have demonstrated levated D2 dopamine receptors in schizophrenia 
(Crawley et al 1986; Wong et al 1986), but these findings could not be replicated inother 
studies (Farde et al 1~88; Martinot et al 19°0). 
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LeFur et al (1980a) initially reported the presence of 3H-spiroperidol binding sites on 
rat and human peripheral lymphocytes as a model of a peripheral D2 dopamine receptor 
site. Consequently, inagreement with the dopamine hypothesis, a significant and selective 
increase in binding capacity (Bm~) for 3H-spiroperidol in lymphocytes of schizophrenic 
patients was described (LeFur et al 1983; Rotstein et al 1983; Bondy et al 1984; Ha[bach 
and Henning 1989; Grodzicki et al 1990). However, selection criteria of patients, meth- 
odological details and even Bm~ and Kd values of healthy subjects have differed widely 
between research groups. 
A similar increase of Bm~ was reported in relatives of schizophrenics (Bondy and 
Ackenheil 1987) and suggests increased 3H-spiroperidol binding as a genetic vulnerability 
marker for schizophrenia. Interestingly, a decreased binding capacity has been detected 
in patients with idiopathic Parkinson's disease (LeFur etal 1980b; Czlonkowska et al 
1987; Bondy et al 1989). 
In contrast, considerable effert in various laboratories tocGrroborate hese results failed 
(Rloxbam et al !981; F'ieminger et al 1982; Maloteaux et al !982; Shaskan et al 1983; 
Feenstra et al 1989; Rao et al 1990). In view of the potential clinical relevance and the 
variety of pitfalls inherent in binding assays using viable cells., the present study reev- 
aluated some methodological issues, including the mathematical procedures applied to 
analyze the data. 
Methods 
Subjects 
Venous blood was collected from 12 healthy men [mean age 28.1 __. 13.1 (__.SD) years] 
between 8:00 and 10:00 AM Subjects with any present illness or under medication, 
alcohol or nicotine abusers, and persons with a history of stressful life events during the 
month prior to the investigation were excluded. 
To control tbr constancy and reproducibility, binding parameters of lymphocytes from 
three subjects were measured in blood samples obtained at least on two separate days. 
The infl:lence of storage on composition of cell suspensions was studied in three subjects 
where the EDTA-blood samples were kept for I, 2, 3, 5, 8, 10, and 12 hr at room 
temperature. 
Cell Preparation 
Peripheral blood mononuclear cells (PBMC) g ere prepared immediately after venipunc- 
ture from EDTA-blood by sodium metrizoate-Ficoll density gradient centrifugation, as 
described elsewhere in detail (Wodarz et al 1991). Briefly, blood was diluted with Hanks 
Balanced Salt Solution (HBSS) without Ca 2 + and Mg 2+ 1/1 (v/v) and layered carefully 
on sodium metrizoate-Ficoli. After centfifugation for 30 min (300 g, 23°C), the lym- 
phocyte,,~ were obtained f~ona the interphase and the granulocytes from the pellet (hemolysis 
of erythrocytes with 0.8% ammonium chloride). Lymphocytes and granuiocytes were 
washed three times !n Hanks Balanced Salt Solution without Ca 2+ and Mg 2+ [1/10 (v/v); 
100 g for 10 rain]. The final cell count was performed with a Coulter Counter (Model 
$5, Coulter Electronics Ltd, GB). Viability of cells always exceeded 98%, as judged 
from their ability to exclude trypan blue (Pappenheimer 1917). Enriched B and T lym- 
phocytes were obtained after culture of unfractionated PBMC for 10 days in culture 
3H-Spiroperidol Binding to PBMC in Man BIOL PSYCHIATRY 293 
1992;31:291-3o3 
medium supplemented with 10 Ixg/ml pokeweed mitogen (PWM) or 10 Ixg/ml phyto- 
hemagglutinin A (PHA). Routine staining was performed to ensure aconstant composition 
of cell suspensions. 
Membrane Preparation 
Crude lymphocyte membranes were prepared from one individual by repeated freeze 
thawing at -80°C. The preparation was hemogenized with a Teflon homogenizer with 
six up-and-down strokes at 1000 rpm. The homogenate was washed three times in HBSS 
without Ca 2+ and ~dg 2+ (20.000 g for 15 min) and used immediately afterwards for a 
saturation experiment. About 13 Ixg per well membrane protein was used. This corre- 
sponded to the amount of viable cells in the binding assays. Protein was determined 
according to Lowry et al (1951). 
Binding Assays 
3H-spiroperidol binding assays were performed immediately after cell separation using 
viable cells (except where otherwise stated). Cells were suspended in HEPES (25 mmol/L) 
buffered HBSS, pH 7.4, including 1.3 mmol/L Ca 2+ and Mg 2+. To determine binding 
parameters, cells were incubated with ten different concentrations of 3H-spiroperidol (30 
pmol/L to 3 nmol/L) in the presence or absence of I l~mol/L (+)-butaclamol in 96-wen 
microtiter plates (NUNC, Sweden). Equilibrium was achieved by incubation at 37°C for 
60 min in a humidified atmosphere (5% CO2; 95% air). To determine saturability of 
binding, 3H-spiroperidol concentrations upto 300 nmol/L were used. Free was separated 
from bound ligand by rapid filtration through polyethyleneimine (PEI; 0.3%; Sigma, St. 
Louis, USA)-pretreated Whatman GF/C filters (Whatrnan, Maidstone, GB) with a Titertek 
semiautomatic cell harvester (How Laboratories, Inc., Rockville, MD) followed by an 
1 l-see wash with ice-cold HBSS. The radioisotope was measured by a standard liquid 
scintillation count in a Beckman LS 5000 TD counter at an efficiency of about 54%. All 
assays were routinely performed in duplicate, except where otherwise stated. 
Determination f Unspecific Filter Binding 
To determine unspecific binding of 3H-spiroperidol to the widely used Whatman GF/B 
and Whatman GF/C glass-fiber filters, a binding assay was performed as described above 
without addition of cells. Different methods were tested to reduce unspecific binding of 
radioligand to the glass-fiber filters (e.g., extended washing time, pretreatment of filters 
with different concentrations of the polycationic polyethylenimine). 
Displacement of 3H-Sp,~roperidol Binding 
Various concentrations of ( + )- and (-)-butaclamol (10-~°-10 -2 mol/L) and GBR 12909 
were used to displace 3FI-spiroperidol from its binding site. 
Chemicals 
3H-spiroperido! (specific activity 85-96 Ci/mmol/L, except where indicated) was obtained 
from Amersham (Braunschweig, Germany). Ammonium chloride, sodium metrizoate- 
Ficoll, trypan b)uc, phytohemagglutinin A, and pokeweed mitogen were obtained from 
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Sigma Chemicals Inc. (St. Louis, USA). GBR 12909 was obtained from Research Bin- 
chemicals Inc. (Natick, USA). 
Culture medium consisted of Rosewell Park Memorial Institute Medium (RPMI) 1640 
(Boehringer, Mannheim, Germany) supplemented with 2 mmol/L L-glutamate, 0.1 mg/ml 
gentamycine, and 10% (v/v) fetal calf serum (all Bioehrom KG, Berlin, Germany). Hanks 
Balanced Salt Solution was obtained from Bioehrom KG (Berlin, Germany), HEPES 
from Serva Chemicals (Heidelberg, Germany), and (+)- and (-)-butaclarnol from Re- 
search Biochemicals Inc. (Wayland, USA). All dilutions were made with HBSS. Because 
some subsets of PBMC are known to adhere to glassware, only plastic material was used 
throughout the experiments. 
Data Analysis 
The term "displaceable binding" defines the difference between binding in the absence 
and in the presence of I Ixmol/L ( + )-butaclamol. Kd and Bm~x values were derived from 
computerized iterative nonlinear egression analysis (Enzfitter, Elsevier Biosoft). The 
Enzfitter software offers the option of weighing the data statistically and excluding "out- 
liers." The same results could be obtained by excluding samples with a coefficient of 
variation within a single experiment exceeding 10%. 
The following equations were used to apalyze the data and to fit the binding curves: 
(a,b) single-site model: 
Bound = (Bmax x Free)/(Kd + Free); 
(c) one specific and one nonspeeific binding site model: 
Bound = (Bmax X Free)/(Kd + Free) + (F x Free), 
where F represents he slope of the nonspecific but displaceable binding; 
(d) two site model: 
Bound = (Bm~t X Free)/(gdt + Free) + (Bronx2 × Free)l(Kd2 + Free). 
To determine whether the increase of goodness of fit for a model with additional parameters 
was significantly more than could be expected on the basis of chance alone, a reliable F 
test was applied: 
F = (SS~ - SS2)/(df~ - df2)/(SS2/df,), 
where S~ and SS2 are the residual sums o' , ]uares of the deviations of the points to the 
fitted curve, and ,:lf~ and dr2 are the assoeiatea degrees of freedom (numbers of data points 
minus number of parameters) for the original model and the model with additional 
parameters, respectively (Munson and Rodbard 1980; Bardsley and McGinlay 1987). 
Results 
Separation of Free from Bound 3H-Spiroperidol 
Using Whatman GF/B filters, 50%-80% of total binding was unspecific binding of ra- 
dioligand to filter material (Figure 1). Only about 5%-15% corresponded todisplaceable 
binding. Moreover, unspecific binding of 3H-spiroperidol to glass-fiber filters increased 
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Figure 1. Counts-per-minute (cpm) 
values of unspecific 3H-spiropefidol 
binding to Whatman GF/B filte~ with 
and without pretreatment wi h 0.3% 
polyethyleneimine [PEI]. Note that 
unspecific filter binding initially was 
higher in the presence of 1 Ixmol/L 
(+)-butaclamol [(4-)-B] as displac- 
ing agent (without (+)-butaclamol 
[G]). Moreover, eduction of unspe- 
cific filter binding by extended wash- 
ing was insufficient. Results are the 
mean of three different experiments 
with 3 nmol/L 3H-spiropefic!ol (to- 
tals: 12,391 cpm); standard evia- 
tions were omitted for reasons of 
clarity. 
to 65%-90% in the presence of ( + )-butaclamol (Figure 1). Consequently, the calculated 
displaceable binding decreased substantially. Figure I demonstrates that extended washing 
halved unspecific filter binding. Pretreating Whatman GF/C filters (results with other 
filter material are not shown) with 0.3% polyethyleneimine (PEI) (Bruns et al 1983) 
reduced unspecific filter binding to 5%-10% of total binding. Moreover, displaceable 
binding increased to 40%-60% of total binding and the experimental intraassay and 
interassay scattering decreased. The coefficient of variance without PEI was 0.36; with 
PEI, it was 0.09. 
Displacement of3H-$piroperidol Biw in8 
The enantiomers of butaclamol exhibite¢, r.o stereoselectivity with high (> 2 nmol/L) 
concentrations of 3H-spiroperidol (Figure 2al. However, by using low (< 1 nmol/L) 
concentrations of 3H-spiroperidol ( +)-bu~aclamol was about 8 times more potent han 
(-)-butaclamol (Figure 2b). GBR 12909, a selective dopamine uptake inhibitor (Heikkila 
and Manzino 1984), was about 100 times more potent han (-)-butaclamol in displacing 
low concentrations of 3H-spiroperidol, but it was hardly effective with high (> 2 nmol/L) 
concentrations of radioligand. 
3H-Spiroperidol Binding to Subsets of Peripheral Blood Mononuclear Cells 
and Membrane Preparations 
We investigated 3H-spiroperidol binding to unfractionated lymphoc3~tes, to enriched B 
and T lymphocyte-suspensions, a d tO granulocytes. The typically sha[~d saturation curve 
(Figure 3) could only be found with unfracfi~,~ted lymphocytes and in enriched B cell 
fractions. T cells and granulocytes xhibited only nonspecific binding within the ligand 
concentration range used (30 pmol/L to 3 nmol/L). 
There was a linear relationship between onspecific binding and the amount of con- 
taminating ranulocytes, that is, the percentage of nonspecific binding increased as the 
number of granulocytes increased (r = 0.88, p < 0.05). Moreover, there wai~; anegative 
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Figure 2. (a) x x, (+)-butaclamol; -- 
-o, (-)-butaclamo]. Results are the mean 
of three different experiments, each carried 
out in triplicate. Displacement curves with 
3 and 0.4 nmol/L were established simul- 
taneously with the same PBMC suspen- 
sions. By using a ligand concentration f 3 
nmol/L 3H-spiroperidoi d splacement curves 
of (+)- and ( - )-butaclamol revealed no 
stereoselectivity. (b) x. x, (+)-butacla- 
mol; o---o, (-)-butaclamol; * . . .  *, GBR 
12909. Results are the mean of three dif- 
ferent experiments, each carried out in tri- 
plicate. Displacement curves with 0.4 and 
3 nmol/L were established simultaneously 
with the same PBMC suspensions. By using 
a ligand concentration of 0.4 nmol/L 3H- 
spiroperidol displacement curves exhibited 
that (+)-butaclamol is about 8 times more 
potent han (-)-butaclamol. GBR 12909, a 
selective dopamine uptake inhibitor, was 
about 100 times more potent han (-)-bu- 
taclamol. 
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Figure 3. Typically atypical 
saturation curve of SH-spiro- 
peridol (ligand concentration 
range: 0,03-3 nmol/L) to un- 
fractionated lymphocytes. The 
in~et displays the linear trans- 
formation by Scathe;hard (I 949). 
Only a total of 2%-4% of free 
ligand was bound to the cells, 
of which 47%--62% was dis- 
placeable by I Dmol/L ( + )- 
butac~amoi. (a) One saturable 
site: Ka = 3.18 - 0.24; Bma~ 
= 7.94 --- 0.64. (b)One sat- 
urable site and omitting the 
nonsaturable part: Kd = 0.38 
-+ 0.02; Bm~ - 1.48 ± 0.03, The visually defined cutoff for omitting the nonsaturable part was 
above 0.5 nmol/L flee iigand. (c) One saturable site and one nonspecific nonsaturable part: g,t = 
0. ~22 _ 0.010; Bm~ = 0,360 +- 0.094. The curve fits were omitted tor reasons of clarity. 
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Table 1. Binding Parameters (B,m, Kd), Dependent on Mode of Calculation ° 
(a) One Saturable Site 
Bidart et at LeFur et at 
(1983) (1980a, 1980b) Wodarz et at 
Kd (nmol/L) 
Bm~ 
(fmol/lO ~ cells) 
2.27 ± ? 5.4 ± 0.5 2.69 - 0.41 
29 --. ? 103 - 4 6.15 ± 0.96 
(b) One Saturable Site and Omitting the Nonsaturable Part 
Hatbach and 
Hemming Grodzicki et at 
(1989) (1990) Wodarz et at 
Kd (nmol/L) 
Bm~ 
(fmol/106 cells) 
Not stated 0.18 ± 0.03 0.36 --- 0.04 
1 ± 0.6 3.4 - 1.2 1.18 - 0.15 
(c) One Saturable Site and One Nonspecific Nonsaturable Part 
Bondy and 
Ackenheil 
(1987) Wodarz et at 
Ed (nmol/L) 0.17 ± 0.07 0.25 ± 0.05 
Bmu 2.66 --. 0.69 0.50 - 0.06 
(fmol/10 e cells) 
q~alculation based on the following asamptions: (a) one saturable site in the ligand conc~:ntmtion ra ge up to 5 nmol/L; 
(b) one saturable site (the nonsaturable part in the ligand concentration range 0.03-3 nmol/L was omitted); Note----Gr~icid 
et al used a ligand concentration range of 0.07-1.2 nmol/L; end (c) one saturable site and one nonspecific nonsaturable part 
within the ligand concentration ra ge 0.03-3 .mol/L. 
correlation between time of storage of EDTA-blood and amount of displaceable binding 
(r = -0.85,  p < 0.05). Routine staining revealed that this was due to an increased 
contamination by granulocytes. 
In crude membrane preparations we were unable to detect displaceable binding. 
Saturation Experiments 
Our experiments in healthy volunteers revealed abiphasic saturation curve with an initial 
pan at low ligand concentrations (< 1 nmol/L), which might be interpreted as a saturable 
binding site and a second linear part with higher ligand concentrations (1-300 nmol/L), 
which is not saturable (Figure 3). 
The mathematical methods described above for the calculation of Bm~ and Kd values 
were applied to this atypically shaped saturation curve (Table 1). 
In 10 of 12 individuals tested, it was not possible to obtain Bn~ and Kd values of two 
saturable binding sites. 
Because the goodness of fit will always improve when additional parameters are added 
to a model, we applied a reliable F test for model discrimination (Munson and Rodbard 
1980; Bardsley and McGinlay 1987). This shows that the model of one specific and one 
nonspecific binding site significantly improves the goodness of fit, and is preferable to 
the simpler model of one single site in the ligand concentration range 0.03-3 ntno]/L 3H- 
spiperone (F = 6.67, dfm - 8, df2 ffi 7, p < 0.05). The single-site model, which omits 
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Table 2. Binding Parameters Kd and B~ (mean "4- SD) of 3H-Spiroperidol Binding to 
Unfractionated Lymphocytes in Three Individuals Tested on Different Days" 
(a) One Saturable Site 
Subject Day Kd (nmol/L) Bm~ (fmol/106 cells) 
1 ! 3.55 - 0.24 9.83 "4" 0.52 
2 2.56 - 0.10 12.01 + 0.75 
2 I 1.99 +- 0.12 '$.81 -4- 0.37 
2 2.81 +-- 0.31 6.69 +- 0.56 
3 1 5.63 4- 0.30 5.88 -- 0.95 
2 4.00 - 0.57 6.97 ± 0.84 
3 3.17 - 0.21 4.09 ± 0.55 
Subject 
(b) One Saturable Site and Omitting the Nonsaturable Part 
Day Ka (nmol/L) Bm~, (fmol/10 ~cells) 
1 1 0.454 _ 0.022 2.261 +_ 0.052 
2 0.449 ± 0.014 2.469.4- 0.375 
2 1 0.191 ± 0.0i9 5.313 ± 0.037 
2 0.227 _+ 0.031 5.026 _+ 0.145 
3 1 0.388 ± 0.021 7.390 ± 0.195 
2 0.295 .4- 0.013 6.209 _ 0.184 
3 0.179 ± 0.021 8.091 _ 0.515 
Subject 
(c) One Saturable Site and One Nonspecific, Nonsaturable Part 
Day Kd (nmol/L) Bm~ (fmol/10 e cells) 
I I 0.121 _ 0.013 0.792 - 0.064 
2 0.134 -- 0.015 0.928 - 0.110 
2 I 0.165 -*- 0.019 0.608 ± 0.032 
2 0.174 ± 0.018 0.719 ± 0.077 
3 I 0.198 ± 0.017 0.238 ± 0.030 
2 0.183 ± 0.011 0.185 ± 0.016 
3 0.179 --. 0.021 0.312 ± 0.035 
"l'he calcuations are based on the assumptions described inthe text. The individual SD is given by the software used for 
nonlinear regression data analysis to indicate the goodness of fit. 
the nonsaturable part (ligand concentration range 0.05-3 nmol/L) (Halbach and Henning 
1989), significantly improves the goodness of fit too (F = 33.6, dr1 ffi 8, df2 - 3, p 
< 0.005). However, this model is not adequate, as discussed later. 
Tl~e Kd and Bm~ values exhibited a considerable variation between individuals, but 
remained relatively constant in repeated measurements intraindividually. The amount of 
interindividual and intraindividual scattering depends on the mode of calculation (see 
Table 2 and SD in Table 1). 
Discussion 
In line with the dopamine hypothesis, LeFur et al (1980a, 1983) reported an increase in 
3H-spiroperidol binding sites on peripheral lymphocytes in schizophrenic patients and a 
decrease of these binding sites in idiopathic Parkinson's disease. Subsequently, these 
exciting results were questioned, because ven the methodology applied could not be 
constantly reproduced in other laboratories. The potential clinical importance of 3H- 
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spiroperidol binding to lymphocytes a  a "vulnerability marker of schizophrenia" (Bondy 
and Ackenheil 1987) led us to reinvestigate he most striking pitfalls in binding assays 
using viable cells. 
Separating free from bound ligand is a critical point in dete__rmination of the chArac- 
teristic binding parameters 8m~ and Kd. Due to a steady-state dissociation constant in 
the nanomolar range, time for the separation procedure should not exceed 30--60 sec. 
Most investigators used a filtration assay, because of its unsurpassed speed, efficiency, 
and easy handling (Fleminger et al 1982; Maloteaux et al 1982; Bidart et al 1983; LeFur 
et al 1983; Shasken et al 1983; Itzchaky et al 1989). A pertinent example of the most 
dangerous pitfall of this technique is the stereospecific binding of mdiolabeled opiates to 
glass-fiber filters reported by Pastemak and Snyder (1975). With mdiolabeled spiroperidol 
only Fleminger et al (1982) mentioned a filter binding of 50% when using the most 
commonly employed Whatman GF/B filters. Other investigators seem not to have con- 
trolled for this phenomenon (Maloteaux et al 1982; Bidart et al 1983; LeFur et al 1983; 
Shaskan et al 1983; Itzeh',&y et al 1989). As demons~lted for various other receptor 
assays (Maayani and Weinstein 1980; Ito et al 1986) the apparent Kd and Bm~ values 
were not meaningful wii~hc,Jt coping with this phenomenon. I  our experiments pretreat- 
ment of Whatman GF/C fii~ers with 0.3% polyethyleneimine (Brans et al 1983; Gundlach 
et al 1984) finally reduc~:d ,mspecific filter binding to 5%-10% of total binding. Moreover, 
displaceable binding in~,:.'r~.ased to 40%--60% of total binding and the experimental in- 
traassay and interassay ~cattering decreased. 
Conflicting results h~w~ been reported for the distribution of 3H-spiroperidol binding 
sites on different subtypes of human peripheral blood mononuclear cells. Bidart et al 
(1983) reported that B lymphocytes had about double the capacity of T lymphocytes to
bind this ligand, whereas Uzan et al (1981) found displaceable binding only on B cells. 
In agreement with Uzan et al (1981) we found displaceable binding only with unfrac- 
tionated lymphocytes and in enriched B cell fractions. Because the amount of contami- 
nating granulocytes contributes ".~ a decrease in percentage of displaceable binding, 
especially in the low concentrati~on ra ge of radiolabeled spiroperidol, it is of critical 
importance to control for a constraint composition of investigated cell suspensions. One 
possibility would be to investigatle pure B cell suspensions, but this needs considerable 
additional methodological effort. If unfractionated cell suspensions are examined, it is 
essential to proceed immediately after blood drawing. Some groups did not refer to that 
(Bloxham et al 1981; Fleminger et al 1982; Bidart et al 1983; Rotstein et al 1983; Bondy 
and Ackenheil 1987; Feenstra et al 1989; Itzchaky et al 1989). For example, this might 
be one explanation for the failure of Feenstra et al (1989) to detect any displaceable 
binding in human lymphocytes, ince this group proceeded 18 hr after venipuncture and 
.did not control for granulocyte contamination. 
The weak or missing stereoselecfivity of (+)- and (-)-butaclamol in displacing 3H- 
spiroperidol from its lymphocytic binding sites is a further topic of controversy. Bloxham 
et al (1981), Maloteaux et al (1982), Fleminger et al (1982), and Rotstein et al (1983) 
used ligand concentrations of 4 or 5 nmol/L in displacement experiments. Indeed, at these 
relatively high (>2 nmol/L) ligand concentrations, the stereoisomers of butaclamol ex- 
hibiteet no stereoselectivity. However, when low (< 1 nmol/L) concentrations of 3H- 
spiroperidol were used in our experiments, ( + )-butaclamol was about 8 times more potent 
than (-)~butaclamol (Figure 2b). This might be indicative Of a specifi~ binding site in 
the low concentration range of radiolabeled spiroperidol. But it is very unlikely that it 
resembles the central D2 dopamine receptor', since (+)-butaclamol is about 1000 times 
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more potent han (-)-butaclaniol indisplacing 3H-spiroperidol from striatal D2 dopamine 
receptors. Moreover, dopamine uptake inhibitors arc ineffective at tile neuronal D2 re- 
ceptor (Seeman 1981; Hitri et al 1991; our own data not shown). 
Provided that these technical problems are considered, a final crucial step is the mode 
of data analysis. Rotstein et al (19~3) and Itzchaky et al (1989) were not able to calculate 
any binding parameters and therefore used counts per minute (cpm) of displaeeable binding 
for comparing schizophrenic with healthy subjects. Due to the atypically shaped saturation 
curve, various ways of calculation of Bm~ and Kd values have been used in the literature. 
It must be noted that none of the authors has statistically analyzed the model used. Oar 
validation of these models by a reliable F test demonstrates that both the single-site model, 
which omits the nonsaturable part (ligand concentration range 0.05-3 nmol/L; Halbach 
and Henning 1989), and the complex model of one saturable and one nonsaturable site 
(ligand concentration range, 0.03-3 nmol/L; Bondy and Ackenheil 1987) significantly 
improve the goodness of fit, and are preferable to the single-site model (ligand concen- 
tration range O. 1-5 nmol/L; LeFur et al 1983; Bidart et ai 1983). The single-site model, 
which omits the nonsaturable part (ligand concentration range 0.05-3 nmol/L; Halbach 
and Henning 1989), is highly prone to bias, since the cutoff point is chosen arbitrarily. 
By using the model of two different binding sites, we were unable to achieve two Kd 
and 8m~ values in 10 of 12 individuals tested. Moreover, with concentrations of radio- 
ligand above 1 nmol/L only a linear nonsaturable increase in binding could be observed, 
in accordance with Feenstra et ai (1989). As long as the molecular nature of the "spi- 
roperidoi binding site" is unknown, the complex model of one saturable and one non- 
saturable site (iigand concentration range 0.03-3 nmol/L; Bondy and Ackenheil 1987) is 
the most adequate. 
Ba~ed on these different calculation strategies, our Bm~ and Kd values in healthy 
subjects corresponded quite well to those of other esearch groups (Table l). The remaining 
discrepancies might be explained by such pitfalls as variable composition of investigated 
cell suspensions (Bidart et al 1983; Benday and Ackenheil 1987) and uncon~trolled un- 
specific filter binding (LeFur et al 1983~. Grodzicki et al (1990) analyzt,d the ligand 
concentration range 0.07-1.2 nmol/L only'. This confirms the need to define exactly the 
details of experimental ~ad mathematical procedures before comparing the results reported 
by different groups. 
111e molecular naturt: of the "3H-spiroperidol binding site" is still unknown. Phar- 
macological characteristic~ are quite differ~:nt from the central D2 dopamine receptor with 
high (Bloxham et al 1981; Fleminger et al 1982; Maloteaux et al 1982) as well as low 
concentrations of aH-spil~rone (see stereoselectivity of butacl~vl-enantiomers). More- 
over, ¢e~,ls have to be viable to demonstrate binding at all (Shaskan et al 1983; Feenstra 
et al 1989; Roe et al 199C~; our own results), whereas neuronal D2 sites can be detected 
in membrane preparations. Taken together with preliminary new results in our (Figure 
2b) and other laboratories (Bondy et al 1990) with the specific dopamine uptake inhibitor 
GBR 12909, the "high-affinity site" resembles an active, energy-dependent transport site 
and not a true receptor. On the other hand, the possibilky that this "binding site" might 
resemble one of the novel clopamine r ceptors (D3,4,5; Sokoloff et al 1990; Van Tel et al 
1991; Sunahara et al 1991) could not be definitely excluded. The "nonGpeeific, nonsa- 
turable" part might represent an unspecific uptake into the cells (Fleminger et al 1982; 
Maloteaux et al 1983). 
Ap~rt from not ~xactly knowing the pharmacological and molecular nature of the "3H- 
spiroperidol binding site" in peripheral lymphocytes, the findings m schizophrenia of 
3H-Spiroperidol Binding to PBMC in Man BIOL F SYCHIATRY 301 
1992;31-291-303 
LeFur et al (1983), Rotstein et al (1983), Bondy and Ackenheil (1987), and Grodzicki 
et al (1990) have not been replicated (Bloxham et al 1981; Fleminger et al 1982; Maloteaux 
et al 1982; Shaskan et al 1983; Feenstra et al 1989; Rao et al 1990). The methodological 
issues discussed here might have contributed to this discrepancy. 
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